Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening

Luise Holzhauser, Ronald Zolty

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Since its discovery in 1988, the endothelin system has been employed in multiple physiological and pathological roles. Endothelin-1 (ET-1) is not only a major regulator of vascular tone and cardiac contractility but also exerts mitogenic effects and is involved in inflammatory responses. ET-1 acts via two endothelin receptors located mainly on smooth muscle and endothelial cells through complex intracellular pathways differing between receptors and cell types. Polymorphisms of the endothelin receptor A have been associated not only with the risk in pulmonary arterial hypertension (PAH), systolic heart failure and systemic hypertension but are also of prognostic significance in dilated cardiomyopathy. Polymorphisms of endothelin receptors might lead to altered endothelin signaling and influence the response to endothelin receptor antagonist therapy in PAH in light of pharmacogenetics. This review will summarize the role of ET-1 within major cardiovascular pathologies and discuss endothelin receptor polymorphisms with special emphasis on potential therapeutic and screening implications.

Original languageEnglish (US)
Pages (from-to)743-758
Number of pages16
JournalHeart Failure Reviews
Issue number6
StatePublished - Oct 11 2014
Externally publishedYes


  • Dilated cardiomyopathy
  • Endothelin receptor polymorphisms
  • Endothelin-1
  • Hypertension
  • Pulmonary hypertension
  • Transplant

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening'. Together they form a unique fingerprint.

Cite this